Skip to main content

Table 1 Baseline characteristic of patients

From: Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial

  n = 60 (%)
Age < 60 28 (46.7%)
≥ 60 32 (53.3%)
Sex Female 12 (20.0%)
Male 48 (80.0%)
ECOG performance status 0 9 (15.0%)
1 51 (85.0%)
Pathologic confirmation No 0 (0.0%)
Yes 60 (100%)
Child-Pugh classification A5 41 (68.3%)
A6 19 (31.7%)
Etiology Hepatitis B 46 (76.7%)
Hepatitis C 6 (10.0%)
Alcohol 1 (1.7%)
Primary biliary cirrhosis 1 (1.7%)
Others 6 (10.0%)
Alpha-fetoprotein ≥ 400 30 (50.0%)
< 400 30 (50.0%)
Extrahepatic disease No 8 (13.3%)
Yes 52 (86.7%)
Prior treatment Transplantation 0 (0.0%)
Surgery 17 (28.3%)
Locoregional therapy (RFA, TACE) 41 (68.3%)
Radiotherapy 31 (51.7%)
Prior chemotherapy 1 48 (80.0%)
≥ 2 12 (20.0%)
Prior sorafenib No 0 (0.0%)
Yes 60 (100%)
  1. ECOG, Eastern Cooperative Oncology Group; RFA, radiofrequency ablation; TACE, transarterial chemoembolization